Chinese Traditional and Herbal Drugs
|
2025, 56(19): 7118-7129
Exploration of medication rules and mechanism of Qingdu Wenxin Formula in treatment of dilated cardiomyopathy based on data mining, network pharmacology and experimental verification
Full
Affiliations
doi: 10.7501/j.issn.0253-2670.2025.19.022
Outline
Objective Based on clinical literature on traditional Chinese medicine (TCM) treatment of dilated cardiomyopathy (DCM), this study analyzed the medication rules and explored the mechanism of action of Qingdu Wenxin Formula (QD-WXF) in the treatment of DCM through network pharmacology and experimental validation. Methods Relevant literature related to the treatment of DCM with traditional Chinese medicine was retrieved from China national knowledge infrastructure (CNKI), Wanfang and VIP databases, establishing a database of traditional Chinese medicine prescriptions after screening. SPSS Modeler and SPSS Statistics were employed for frequency analysis, association rules and cluster analysis to summarize the medication rules and identify the core formula. Active ingredients and corresponding targets of QD-WXF were screened via traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), Swiss Target Prediction and Swiss ADME. InteractiVenn was used to obtain the intersection of the corresponding drugs and disease targets, construct protein-protein interaction (PPI) networks, and screen core targets to build a “drug-ingredient-target” interaction network. The Metascape database was used for gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses. Based on the above analysis, an in-vivo model of doxorubicin-induced DCM in mice was used for experimental verification. Results A total of 124 articles were included, covering 131 prescriptions and 166 flavors of TCM, with a total of 1 424 drug use frequencies. A total of 32 herbs occurred ≥10 times. The top five TCMs were Huangqi (Astragali Radix), Fuling (Poria), Danshen (Salviae Miltiorrhizae Radix et Rhizoma), Gancao (Glycyrrhizae Radix et Rhizoma), and Guizhi (Cinnamomi Ramulus), among them, the TCM with detoxification effects were Yimucao (Leonuri Herba), Shengma (Cimicifugae Rhizoma), and Huanglian (Coptidis Rhizoma). On the basis of replenishing qi, warming yang, activating blood circulation and removing blood stasis, the QD-WXF was obtained by optimizing the compatibility. Network pharmacological analysis of QD-WXF resulted in 177 drug-disease intersection targets and ten core active ingredients of the drug, and seven core targets were identified through PPI network analysis. KEGG analysis showed significant enrichment in the Apelin signaling pathway, calcium signaling pathway, etc. In-vivo experiments confirmed that QD-WXF markedly improved cardiac function and treat DCM induced by doxorubicin. Conclusion Current TCM in treatment of DCM mainly focuses on replenishing qi, warming yang, and promoting blood circulation to resolve stasis. QD-WXF was obtained based on the analysis of the theory of toxic pathogen and data mining results. Its major active ingredients act on potential targets such as proto-oncogene tyrosine-protein kinase Src (SRC), mitogen-activated protein kinase 1 (MAPK1) and MAPK3 and other potential targets, and it plays a therapeutic role in signaling pathways such as Apelin and Calcium ion. QD-WXF can improve doxorubicin-induced DCM, and its mechanism may be related to the regulation of SRC/protein kinase B (AKT)/ extracellular regulated kinase (ERK) signaling pathway.
dilated cardiomyopathy
/
Qingdu Wenxin Formula
/
data mining
/
network pharmacology
/
SRC/AKT/ERK signaling pathway
赵江峰, 徐江林, 何佳乐, 杨智, 王军, 岳建伟, 道力根, 李春, 王伟.
基于数据挖掘、网络药理学及实验验证探究清毒稳心方治疗扩张型心肌病的用药规律及作用机制.
中草药,
2025
, 56
(19)
: 7118
-7129
.
DOI: 10.7501/j.issn.0253-2670.2025.19.022
ZHAO Jiangfeng, XU Jianglin, HE Jiale, YANG Zhi, WANG Jun, YUE Jianwei, DAO Ligen, LI Chun, WANG Wei.
Exploration of medication rules and mechanism of Qingdu Wenxin Formula in treatment of dilated cardiomyopathy based on data mining, network pharmacology and experimental verification[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(19)
: 7118
-7129
.
DOI: 10.7501/j.issn.0253-2670.2025.19.022
Year 2025 volume 56 Issue 19
49
10
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.19.022
- Receive Date:2025-08-03
- Online Date:2026-11-13